264 related articles for article (PubMed ID: 8615057)
1. Effects of gemfibrozil (Lopid) on hyperlipidemia in acitretin-treated patients. Results of a double-blind cross-over study.
Vahlquist C; Olsson AG; Lindholm A; Vahlquist A
Acta Derm Venereol; 1995 Sep; 75(5):377-80. PubMed ID: 8615057
[TBL] [Abstract][Full Text] [Related]
2. Effects of regular and extended-release gemfibrozil on plasma lipoproteins and apolipoproteins in hypercholesterolemic patients with decreased HDL cholesterol levels.
Schaefer EJ; Lamon-Fava S; Cole T; Sprecher DL; Cilla DD; Balagtas CC; Rowan JP; Black DM
Atherosclerosis; 1996 Nov; 127(1):113-22. PubMed ID: 9006811
[TBL] [Abstract][Full Text] [Related]
3. Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study.
Aguilar-Salinas CA; Fanghänel-Salmón G; Meza E; Montes J; Gulías-Herrero A; Sánchez L; Monterrubio-Flores EA; González-Valdez H; Gómez Pérez FJ
Metabolism; 2001 Jun; 50(6):729-33. PubMed ID: 11398153
[TBL] [Abstract][Full Text] [Related]
4. Long-term use of gemfibrozil (Lopid) in the treatment of dyslipidemia.
Lewis JE
Angiology; 1982 Sep; 33(9):603-12. PubMed ID: 6957156
[TBL] [Abstract][Full Text] [Related]
5. Treatment of hypercholesterolemia and combined hyperlipidemia with simvastatin and gemfibrozil in patients with NIDDM. A multicenter comparison study.
Tikkanen MJ; Laakso M; Ilmonen M; Helve E; Kaarsalo E; Kilkki E; Saltevo J
Diabetes Care; 1998 Apr; 21(4):477-81. PubMed ID: 9571327
[TBL] [Abstract][Full Text] [Related]
6. Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia.
Durrington PN; Mackness MI; Bhatnagar D; Julier K; Prais H; Arrol S; Morgan J; Wood GN
Atherosclerosis; 1998 May; 138(1):217-25. PubMed ID: 9678787
[TBL] [Abstract][Full Text] [Related]
7. Randomized crossover study of gemfibrozil versus lovastatin in familial combined hyperlipidemia: additive effects of combination treatment on lipid regulation.
Zambón D; Ros E; Rodriguez-Villar C; Laguna JC; Vázquez M; Sanllehy C; Casals E; Sol JM; Hernández G
Metabolism; 1999 Jan; 48(1):47-54. PubMed ID: 9920144
[TBL] [Abstract][Full Text] [Related]
8. Changes of lipoprotein profile in familial dysbetalipoproteinemia with gemfibrozil.
Zhao SP; Smelt AH; Leuven JA; Vroom TF; van der Laarse A; van 't Hooft FM
Am J Med; 1994 Jan; 96(1):49-56. PubMed ID: 8304363
[TBL] [Abstract][Full Text] [Related]
9. Effects of a lipid lowering fibrate and hormone replacement therapy on serum lipids and lipoproteins in overweight postmenopausal women with elevated triglycerides.
Nerbrand C; Nyberg P; Nordström L; Samsioe G
Maturitas; 2002 May; 42(1):55-62. PubMed ID: 12020980
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of fenofibrate or gemfibrozil on serum lipid profiles in Chinese patients with type IIb hyperlipidemia: a single-blind, randomized, and cross-over study.
Jen SL; Chen JW; Lee WL; Wang SP
Zhonghua Yi Xue Za Zhi (Taipei); 1997 Apr; 59(4):217-24. PubMed ID: 9216117
[TBL] [Abstract][Full Text] [Related]
11. Effects of gemfibrozil on very-low-density lipoprotein composition and low-density lipoprotein size in patients with hypertriglyceridemia or combined hyperlipidemia.
Yang CY; Gu ZW; Xie YH; Valentinova NV; Yang M; Yeshurun D; Quion JA; Gotto AM
Atherosclerosis; 1996 Sep; 126(1):105-16. PubMed ID: 8879439
[TBL] [Abstract][Full Text] [Related]
12. Fenofibrate of gemfibrozil for treatment of types IIa and IIb primary hyperlipoproteinemia: a randomized, double-blind, crossover study.
Insua A; Massari F; Rodríguez Moncalvo JJ; Rubén Zanchetta J; Insua AM
Endocr Pract; 2002; 8(2):96-101. PubMed ID: 11942772
[TBL] [Abstract][Full Text] [Related]
13. A comparison of lovastatin, an HMG-CoA reductase inhibitor, with gemfibrozil, a fibrinic acid derivative, in the treatment of patients with diabetic dyslipidemia.
Bell DS
Clin Ther; 1995; 17(5):901-10. PubMed ID: 8595642
[TBL] [Abstract][Full Text] [Related]
14. Intensive lipid-lowering strategy in patients with diabetes mellitus.
Kanters SD; Algra A; de Bruint TW; Erkelens DW; Banga JD
Diabet Med; 1999 Jun; 16(6):500-8. PubMed ID: 10391399
[TBL] [Abstract][Full Text] [Related]
15. Treatment of combined hyperlipidemia with fluvastatin and gemfibrozil, alone or in combination, does not induce muscle damage.
Smit JW; Jansen GH; de Bruin TW; Erkelens DW
Am J Cardiol; 1995 Jul; 76(2):126A-128A. PubMed ID: 7604787
[TBL] [Abstract][Full Text] [Related]
16. Gemfibrozil in hyperlipidaemia: an open, single blind trial.
Varthakavi PK; Turakhia DP; Sharma SS; Salgaonkar DS; Nihalani KD; Joshi VR
J Assoc Physicians India; 1990 Feb; 38(2):136-40. PubMed ID: 2380132
[TBL] [Abstract][Full Text] [Related]
17. Effect of gemfibrozil on serum lipids in man.
Fenderson RW; Deutsch S; Menachemi E; Chin B; Samuel P
Angiology; 1982 Sep; 33(9):581-93. PubMed ID: 6751166
[TBL] [Abstract][Full Text] [Related]
18. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group.
Frick MH; Syvänne M; Nieminen MS; Kauma H; Majahalme S; Virtanen V; Kesäniemi YA; Pasternack A; Taskinen MR
Circulation; 1997 Oct; 96(7):2137-43. PubMed ID: 9337181
[TBL] [Abstract][Full Text] [Related]
19. Influence of gemfibrozil and clofibrate on metabolism of cholesterol and plasma triglycerides in man.
Kesäniemi YA; Grundy SM
JAMA; 1984 May; 251(17):2241-6. PubMed ID: 6368883
[TBL] [Abstract][Full Text] [Related]
20. Cerivastatin in the treatment of mixed hyperlipidemia: the RIGHT study. The Cerivastatin Study Group. Cerivastatin Gemfibrozil Hyperlipidemia Treatment.
Farnier M
Am J Cardiol; 1998 Aug; 82(4B):47J-51J. PubMed ID: 9737646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
